
    
      OBJECTIVES: I. Compare the efficacy, safety, and pharmacokinetics of 2 different treatment
      schedules of CT-2584 in patients with hormone refractory, metastatic adenocarcinoma of the
      prostate.

      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment
      arms: Arm I: Patients receive CT-2584 IV over 6 hours daily for 3 days every 3 weeks. Arm II:
      Patients receive CT-2584 IV over 6 hours once every 7 days for 3 weeks. Courses repeat every
      3 weeks in the absence of disease progression or unacceptable toxicity.

      PROJECTED ACCRUAL: Approximately 80 patients will be accrued for this study.
    
  